University of North Dakota

UND Scholarly Commons
Physician Assistant Scholarly Project Posters

Department of Physician Studies

2015

Alpha Lipoic Acid: A Potential Therapeutic Option
for Painful Peripheral Neuropathies
Jessica Curcio
University of North Dakota

Follow this and additional works at: https://commons.und.edu/pas-grad-posters
Part of the Nervous System Diseases Commons
Recommended Citation
Curcio, Jessica, "Alpha Lipoic Acid: A Potential Therapeutic Option for Painful Peripheral Neuropathies" (2015). Physician Assistant
Scholarly Project Posters. 95.
https://commons.und.edu/pas-grad-posters/95

This Poster is brought to you for free and open access by the Department of Physician Studies at UND Scholarly Commons. It has been accepted for
inclusion in Physician Assistant Scholarly Project Posters by an authorized administrator of UND Scholarly Commons. For more information, please
contact zeineb.yousif@library.und.edu.

Alpha Lipoic Acid:
A potential therapeutic option for painful peripheral neuropathies
By Dr. Jessica Curcio
Abstract
• Peripheral neuropathy (PN) is a major public health concern.
• There are many etiologies for PN including injury, infection,
toxicity, genetics, metabolic disease and nutritional deficiencies.
• Alpha lipoic acid (ALA), also known as thioctic acid, is a potent
antioxidant and cofactor in many cellular metabolic processes.
• Oxidative damage plays a significant role in the pathogenesis of
both diabetic peripheral neuropathy (DPN) and chemotherapy
induced peripheral neuropathy (CIPN).
• Because of the antioxidant capability ALA has been studied for
its potential benefit in preventing and treating PN

Introduction
•
•
•
•

Peripheral neuropathy is prevalent among diabetic patients and patients
receiving chemotherapy.
PN is a conduction deficit that affects the peripheral nerves secondary to
damage of the nerve axons or myelin sheaths.
The affected nerves can be either sensory or motor.
Affected sensory neurons can be either the small sensory receptors, which
affect pain and temperature sensation or large sensory fibers, which lead to a
deficit in proprioception and vibration.

Statement of the Problem
•
•
•
•
•

Peripheral neuropathy is an important clinical challenge in both diabetics and
patients undergoing chemotherapy.
The symptoms include burning, tingling, shooting pains as well as numbness.
These symptoms are often debilitating and cause a significant impact on quality
of life, morbidity and mortality in these populations.
Studies have reported that up to 50% of diabetic patients and up to 80% of
patients receiving chemotherapy will experience PN (Argyriou, Bruna,
Marmiroli, & Cavaletti, 2012; Tesfaye & Selvarajah, 2012).
Therapeutic options thus far include antidepressants, anti-epileptic and opioid
analgesics, that have limited efficacy for PN but cause a variety of unwanted
side effects.

Research Question
 In patients with peripheral neuropathy can alpha lipoic acid vs no/other therapy improve
neuropathic symptoms?

Literature Review
Peripheral Neuropathy
 Neuropathic pain is “pain arising as a direct consequence of a lesion or disease
affecting the somatosensory system either at peripheral or central level”
(Haanpaa et al., 2011).
 Symptoms of numbness, tingling and pain often first in the distal lower
extremities and progressing proximally (Hosseini & Abdollahi, 2013).
Pathogenesis of Diabetic Peripheral Neuropathy
 DPN is common affecting up to 50% of diabetics the economic burden exceeds
ten billion dollars per year (Rathur & Boulton, 2005).
 In DPN chronic hyperglycemia creates oxidative stress in overlapping
pathways. This includes; the polyol, hexosamine and protein kinase C pathways
(Edwards, Vincent, Cheng, & Feldman, 2008).
 The generation of free radicals resulting in oxidative stress is thought to be a
major contributor to the development of DPN (Yagihashi, Mizukami, &
Sugimoto, 2011).
Pathogenesis of Chemotherapy Induced Peripheral Neuropathy
 Chemotherapeutic agents also lead to peripheral neuropathy as a fairly common
side effect. This is a serious complication that can lead to reduction in dose or
discontinuation of life-saving therapy (Rock & DeMichele, 2003).
 Oxidative stress is thought to play a critical role in the development of CIPN.
Chemotherapeutic drugs result in the enhancement and accumulation of
reactive oxygen species and result in damaging effect on mitochondria as well
as DNA (Carozzi, Canta, Chiorazzi, & Cavaletti, 2014).
Mechanism of Action of Alpha Lipoic Acid
 An antioxidant is defined as “any substance that, when present in very low
concentrations compared to that of an oxidizable substrate, significantly delays
or inhibits the oxidation of that substrate” (Halliwell & Gutteridge, 1995).
 ALA acts as a potent antioxidant with the ability to scavenge ROS (Gomes &
Negrato, 2014).
Alpha Lipoic Acid and Diabetic Peripheral Neuropathy
 1160 patients and when examined as a group the data from pooled studies
suggest that 600 mg of intravenous ALA daily for 3 weeks improved sensory
symptoms and neuropathic deficits.(McIlduff & Rutkove, 2011; Mijnhout,
Kollen, Alkhalaf, Kleefstra, & Bilo, 2012).
 A prospective observational study compared carbamazepine, pregabalin, or
ALA and followed over 6 months. Pregabalin and ALA outperformed
carbamazepine, however the pregabalin group had a faster onset of symptom
improvement. Lowers dose, 200mg, ALA was used (Patel, Mishra, Patel, &
Dikshit, 2014).
 A retrospective study examined the effects of switching patients on ALA 600
mg for 5 years to gabapentin. In the treatment group 45% of the patients had to
discontinue the gabapentin due to SE. Gabapentin was associated with more
frequent visits, higher cost and greater side effect without any added efficacy
benefit (Ruessmann & German Society of out patient diabetes centres AND
(Arbeitsgemeinschaft niedergelassener diabetologisch tatiger Arzte e.V.), 2009).
 Multicenter RCT determined that oral ALA was effective in the treatment of
DPN in a non-dose dependent manner. Further the study found that 600 mg/day
would be the optimum dose of ALA to use as it was efficacious and lacked
significant GI side effects (Ziegler et al., 2006a).
 Multicenter RCT, to determine the impact of ALA on diabetic peripheral
neuropathy over 4 years. The study failed to demonstrate any difference
between treatment groups. (Ziegler et al., 2011).
Alpha Lipoic Acid and Chemotherapy Induced Peripheral Neuropathy
 Pilot study investigated the therapeutic potential of ALA for cumulative CIPN
in patients being treated with oxaliplatin. Patients received 600 mg of
intravenous ALA weekly for 3-5 weeks and then 600 mg three times a day
orally. The study found the 53% of the patients reported that the side effect of
CIPN was effectively reduced. (Gedlicka, Scheithauer, Schull, & Kornek,
2002).
 Pilot study examined the potential for ALA to counteract docetaxel plus
cisplatin found that almost 43% of the patients had improvement in symptoms
with a median response time of 4 weeks (Gedlicka, Kornek, Schmid, &
Scheithauer, 2003a).
 RCT examined if ALA could attenuate the risk of developing severe PN
symptoms in patients treated with platinum-based chemotherapy. Patients were
randomly assigned to 600 mg of ALA orally vs placebo while receiving
chemotherapy and followed over 24 weeks. The study failed to demonstrate any
significant difference between treatment and placebo in preventing
neurotoxicity. At the end of the study only 28% of the treatment group and 30%
of the placebo group remained for statistical analysis. (Guo et al., 2013a).

Applicability to Clinical
Practice

Discussion
 Two smaller studies found benefit in combination treatment of ALA with other
antioxidants (Bertolotto & Massone, 2012; Vasudevan et al., 2014).
 A prospective study examined ALA against pregabalin and carbamazepine (Patel
et al., 2014). This group used a lower dose of ALA, only 200 mg orally per day,
than had been previously reported as efficacious which is 600 mg per day.
(Mijnhout et al., 2012). ALA did prove efficacious at symptom improvement,
however pregabalin outperformed ALA in speed of onset.
 Two larger RCT that were published by the same group. The first, found that the
lower dose of 600mg orally per day improved symptom scores while minimizing
GI effects (Ziegler et al., 2006b). The second failed to demonstrate any
meaningful response of ALA vs placebo after 4 years. However, this was in part
due to lack of progression of PN symptoms in the placebo group (Ziegler et al.,
2011). This study did demonstrate improvement overall in the treatment group
from baseline.
 The inclusion and analysis of earlier studies of ALA and DPN demonstrates a
clear benefit using 600mg ALA daily with improvement starting as early as 3
weeks and with limited side effects (Ziegler et al., 2004). Studies published
more recently do support the previous findings, however given the inconsistent
study designs and poor power, larger studies should be performed before broad
recommendations.
 Animal studies that have examined the effects of ALA on CIPN are encouraging.
Rodent models of CIPN and ALA have demonstrated efficacy in reversing
allodynia and hyperalgesia (Joseph et al., 2008; Trevisan et al., 2013). Another
animal study supports these finding demonstrating that ALA increases pain
threshold and improves strength in CIPN (Bhadri et al., 2013). One rodent study
was even able to demonstrate that pre-treatment with ALA prevented allodynia
(Trevisan et al., 2013).
 The human clinical trial data for ALA and CIPN is very limited. Results of two
small pilot studies did demonstrate that 600 mg iv ALA for 3 weeks followed by
600 mg ALA three times daily orally effectively reduced symptoms of CIPN in
more than half of the patients (Gedlicka et al., 2002; Gedlicka, Kornek, Schmid,
& Scheithauer, 2003b). In contrast, more recently a study failed to demonstrate
that ALA could attenuate the development of CIPN (Guo et al., 2013b). This
particularly study was not able to reach completion due to the dropout of patients
from both treatment and placebo groups.

• Despite how common PN is and the burden of the disease, currently there
is no efficacious way to halt the progression of the development, other
than tight glucose control in diabetes.
• ALA is a potent antioxidant and has been used for decades in Germany as
an approved treatment for DPN. Studies have demonstrated the efficacy of
ALA for symptoms of DPN and it has an excellent safety profile.
• It would seem reasonable that one could offer patients the option of using
ALA for DPN for a three month trial, if not cost prohibitive, particularly if
side effects from conventional medications are too cumbersome.
• No solid evidence to support the use of ALA for CIPN. There is also some
concern with using antioxidants during chemotherapeutic and radiation
treatment regimens.
• However, CIPN is a significant complication from chemotherapy and can
be quite devastating to patients. Current treatments offered, including
SSRI’s, TCA’s and sodium channel blockers have not proven to be greatly
effective.
• Given that, further studies must be designed that examine the potential for
ALA in treating CIPN. Until then, we must be guarded against broad
recommendations for ALA in CIPN.
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